Inflammatory opacities of the vitreous in rifabutin-associated uveitis.
OBJECTIVE
To describe rifabutin-associated uveitis with opacities in the inferior and posterior vitreous in three patients with acquired immunodeficiency syndrome.


METHODS
Case reports of the three patients are presented.


RESULTS
The patients, who were being treated with rifabutin and fluconazole, developed anterior and posterior uveitis. The posterior uveitis was characterized by white-yellow inflammatory opacities located in the inferior and posterior vitreous. Discontinuation of rifabutin and the start of topical corticosteroid therapy resulted in improvement of the uveitis and visual acuity.


CONCLUSIONS
Recognition of rifabutin-associated uveitis with opacities in the inferior and posterior vitreous may prevent unnecessary invasive diagnostic and therapeutic procedures.
Chaknis
M J
MJ
Department of Ophthalmology, Medical College of Georgia, Augusta 30912, USA.
Brooks
S E
SE
Mitchell
K T
KT
Marcus
D M
DM
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy; D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D005128:Eye Diseases / Q000139:chemically induced / Q000473:pathology; D005260:Female; D015725:Fluconazole / Q000627:therapeutic use; D006801:Humans; D008297:Male; D017828:Rifabutin / Q000009:adverse effects*; D014606:Uveitis, Anterior / Q000139:chemically induced* / Q000473:pathology; D015866:Uveitis, Posterior / Q000139:chemically induced* / Q000473:pathology; D014792:Visual Acuity; D014822:Vitreous Body / Q000187:drug effects* / Q000473:pathology
D000900:Anti-Bacterial Agents; D017828:Rifabutin; D015725:Fluconazole